SCHEMBL23833302

SCHEMBL23833302

CC(C)(C)OC(=O)N[C@@H](CCC(N)=O)COc1cccc(C#CCCO)c1Cl

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AAK1 Q2M2I8 7/20 0.39
▸ HDAC3 O15379 3/20 0.32
▸ HDAC4 P56524 3/20 0.32
▸ HDAC1 Q13547 3/20 0.32
▸ HDAC7 Q8WUI4 3/20 0.32
▸ HDAC2 Q92769 3/20 0.32
▸ HDAC10 Q969S8 3/20 0.32
▸ HDAC11 Q96DB2 3/20 0.32
▸ HDAC8 Q9BY41 3/20 0.32
▸ HDAC6 Q9UBN7 3/20 0.32
▸ HDAC9 Q9UKV0 3/20 0.32
▸ HDAC5 Q9UQL6 3/20 0.32
▸ ATM Q13315 1/20 0.32
▸ SYK P43405 1/20 0.32
▸ CTSL P07711 1/20 0.32
▸ APP P05067 1/20 0.31
▸ ADRB2 P07550 1/20 0.31
▸ REN P00797 1/20 0.31
▸ EPHX2 P34913 2/20 0.31
▸ PTGER1 P34995 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23833306 1.00 AAK1 (0.39) AAK1HDAC3HDAC4HDAC1HDAC7
SCHEMBL27008202 0.93 AAK1 (0.40) AAK1HDAC3HDAC4HDAC1HDAC7
SCHEMBL27134958 0.93 AAK1 (0.40) AAK1HDAC3HDAC4HDAC1HDAC7
SCHEMBL23833062 0.91 AAK1 (0.38) AAK1HDAC3HDAC4HDAC1HDAC7
SCHEMBL22525532 0.91 AAK1 (0.38) AAK1HDAC3HDAC4HDAC1HDAC7
SCHEMBL23833339 0.91 AAK1 (0.38) AAK1HDAC3HDAC4HDAC1HDAC7
SCHEMBL30169109 0.90 AAK1 (0.40) AAK1HDAC3HDAC4HDAC1HDAC7
SCHEMBL22526123 0.90 AAK1 (0.40) AAK1HDAC3HDAC4HDAC1HDAC7
SCHEMBL23833324 0.87 AAK1 (0.41) AAK1SYKPTGER1
SCHEMBL23833326 0.87 AAK1 (0.41) AAK1SYKPTGER1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240016942-A1 STAT DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2024-01-18 — — US disclosed
US-20240016942-A1 STAT DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2024-01-18 — — US disclosed
EP-4121055-A1 STAT DEGRADERS AND USES THEREOF Kymera Therapeutics, Inc. (US) 2023-01-25 — — EP disclosed
WO-2021188696-A1 STAT DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2021-09-23 — — WO disclosed
WO-2021188696-A1 STAT DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2021-09-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240016942-A1 STAT DEGRADERS AND USES THEREOF STAT4, STAT1, STAT3 AAK1 2860/4885HDAC3 184/4885HDAC4 347/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback